238. ビタミンＤ抵抗性くる病/骨軟化症 Vitamin D-resistant rickets Clinical trials / Disease details

臨床試験数 : 28 / 薬物数 : 20 - (DrugBank : 9) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 16

13 trials found

diseases per page:

Showing 1 to 10 of 13 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05357573 (ClinicalTrials.gov)	August 11, 2022	27/4/2022	Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23in Adult Chinese Patients With TIO ...	An Open-Label, Multi Center, Single-Cohort, Post-Marketing Phase 4 Study to Evaluate the Efficacy, P ...	Tumor-Induced Osteomalacia (TIO)	Drug: KRN23	Kyowa Kirin Co., Ltd.	NULL	Recruiting	18 Years	N/A	All	10	Phase 4	China
2	NCT04842032 (ClinicalTrials.gov)	October 5, 2021	30/3/2021	Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23in Pediatric Chinese Patients With ...	An Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, P ...	X-linked Hypophosphatemia (XLH)	Drug: KRN23	Kyowa Kirin Co., Ltd.	NULL	Recruiting	1 Year	12 Years	All	28	Phase 4	China
3	NCT04842019 (ClinicalTrials.gov)	August 30, 2021	30/3/2021	Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23in Adult Chinese Patients With XLH ...	An Open-label, Multi-center, Single-cohort, Post-marketing Phase 4 Study to Evaluate the Efficacy, P ...	X-linked Hypophosphatemia (XLH)	Drug: KRN23	Kyowa Kirin Co., Ltd.	NULL	Recruiting	18 Years	65 Years	All	18	Phase 4	China
4	NCT04320316 (ClinicalTrials.gov)	July 31, 2020	11/3/2020	A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)	An Open Label Trial to Assess the Safety and Efficacy of KRN23, an Investigational Antibody to FGF23 ...	Epidermal Nevus Syndrome	Drug: Crysvita (burosumab-twza) Treatment	University of Alabama at Birmingham	Ultragenyx Pharmaceutical Inc	Completed	6 Months	N/A	Male	1	Phase 4	United States
5	NCT03581591 (ClinicalTrials.gov)	January 31, 2018	27/10/2017	Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypop ...	An Open Label Trial to Assess the Safety and Efficacy of Burosumab (KRN23), an Investigational Antib ...	Hypophosphatemia;Hypophosphatemic Rickets;Pain, Chronic	Biological: Burosumab	Redwood Dermatology Sciences	Ultragenyx Pharmaceutical Inc	Completed	N/A	18 Years	Female	1	Phase 3	United States
6	JPRN-JapicCTI-205284	09/1/2018	11/05/2020	A Study of KRN23 in Adult and Pediatric Patients with X-linked Hypophosphatemic Rickets/Osteomalacia	Phase 3 Long-term Extension Study of KRN23in Patients with X-linked Hypophosphatemic Rickets/Osteoma ...	Adult or pediatric XLH	Intervention name : burosumab INN of the intervention : KRN23 Dosage And administration of the interve ...	Kyowa Kirin Co., Ltd.	NULL	complete			BOTH	27	Phase 3	Japan, Asia except Japan
7	NCT04308096 (ClinicalTrials.gov)	January 9, 2018	26/2/2020	A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia	A Phase 3 Long-term Extension Study of KRN23in Patients With X-linked Hypophosphatemic Rickets/Osteo ...	XLH	Drug: KRN23	Kyowa Kirin Co., Ltd.	NULL	Completed	N/A	N/A	All	27	Phase 3	Japan;Korea, Republic of
8	JPRN-JapicCTI-173614	31/7/2017	15/06/2017	A Study of KRN23 in Pediatric Patients with X-linked Hypophosphatemic Rickets/Osteomalacia	A Phase 3 Open-Label Trial to Assess the Efficacy and Safety of KRN23in Pediatric Patients with X-li ...	X-linked Hypophosphatemic Rickets/Osteomalacia	Intervention name : KRN23 INN of the intervention : burosumab Dosage And administration of the interve ...	Kyowa Kirin Co., Ltd.	NULL	complete	1	12	BOTH	10	Phase 3	Japan
9	NCT03233126 (ClinicalTrials.gov)	July 6, 2017	11/7/2017	A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia	A Phase 3 Open-Label Trial to Assess the Efficacy and Safety of KRN23in Pediatric Patients With X-li ...	X-linked Hypophosphatemic Rickets/Osteomalacia	Drug: KRN23	Kyowa Kirin Co., Ltd.	NULL	Completed	1 Year	12 Years	All	16	Phase 3	Japan
10	NCT02722798 (ClinicalTrials.gov)	April 2016	7/3/2016	A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome	A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23in Patients With Tumor-Induced ...	Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome	Drug: KRN23	Kyowa Kirin Co., Ltd.	NULL	Completed	18 Years	N/A	All	14	Phase 2	Japan;Korea, Republic of

First Previous1 2Next Last